ArQule, Inc. to Present at UBS Global Life Sciences Conference on September 21, 2009
WOBURN, Mass.-(Business Wire)-September 14, 2009 - ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the UBS Global Life Sciences Conference on Monday, September 21, 2009 at 10:30 a.m. eastern time. ArQule’s presentation will be web cast live and can be accessed through the investor relations section of the Company’s website, www.arqule.com. The conference will be held at the Grand Hyatt Hotel, New York.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. An additional clinical-stage program includes compounds that activate the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
